While it is known that mice with genetic immune defects are useful for establishing durable engraftment of human tumor xenografts, the relative role of components of host innate and adoptive immunity in engraftment has not been determined. We directly compared the ability of four strains of genetically immunodeficient mice (NOD/SCID, SCID, Nude and Rag-1-deficient) to successfully engraft and support the human cell lines Daudi, Raji, Namalwa and Molt-4 as subcutaneous tumors. We additionally examined the effect of further immunosuppression of the mice by whole body irradiation at a dose of 600 cGy for Nude and Rag-1 and 300 cGy for SCID mice and by administration of anti-natural killer (asialo-GM1) antibody on tumor growth. Mice with each of the defects supported xenografts to varying degrees. We found differences in growth characteristics in the cell lines tested, with Namalwa consistently producing the largest tumors. With all cell lines studied, optimal growth was achieved using NOD/SCID mice. Overall, tumor growth was somewhat enhanced by pretreatment with radiation with little additional benefit from the addition of anti-asialo-GM1 antibody. The importance of multiple components of the innate and adoptive immune system in xenotransplantation were best demonstrated when results in untreated NOD/SCID mice were compared to SCID, nude and RAG-1-deficient mice. The NOD/SCID mouse with or without additional immunosuppression provides the optimal model for the study of the biology and treatment of human leukemias and lymphomas.
Introduction
Mice with genetically determined immunodeficiencies are potentially useful for studying the growth and behavior of foreign tissues, including human tumors. Since the 1960s, mice with the Nude mutation have been the standard for establishing in vivo models of human malignancies. This strain's value in growing human leukemias and lymphomas has been well described, 1,2 but residual immunity can interfere with transplantability. A mouse strain with a genetic defect causing severe combined immunodeficiency (SCID) was developed in the 1980s. [3] [4] [5] Previous studies from this and other laboratories have confirmed the ability of the SCID mouse to grow a variety of human leukemias and lym-phomas. [6] [7] [8] [9] [10] [11] A mouse strain with another genetic mutation involving the Rag-1 gene has been developed 12 and most recently the SCID mutation was backcrossed into the NOD/Lt strain resulting in an animal with multiple immunologic defects. 13 Several studies have compared growth of human tumors in SCID and Nude mice. [14] [15] [16] [17] [18] [19] To our knowledge, to date no studies have directly compared xenogeneic transplantation in NOD/SCID, SCID, nude and Rag-1 mice. The present study's purpose was to compare the ability of mice with NOD/SCID, SCID, Nude, or Rag-1 genetic defect to permit the growth of selected human lymphoma and leukemia cell lines. This study permitted further evaluation of the addition of whole body irradiation and additional immunosuppression with asialo-GM1, an antibody directed against murine natural killer (NK) cells.
Materials and methods

Animals
Four strains of immune-deficient mice were used for these studies: athymic nude (NCr nu/nu) male mice from the National Cancer Institute; CB-17 severe combined immunodeficient (C.B-17/IcrTac-scidfDF) male mice from Taconic (Germantown, NY, USA); Rag-1 (B6, 129-Rag1tm1Mom) male and female mice from Jackson Laboratories (Bar Harbor, ME, USA) were obtained at 5-7 weeks of age; and NOD/LtS 2 -scid mice were originally obtained from the Jackson Laboratory and locally bred. All mice were maintained in autoclaved micro-isolator cages in a specific pathogen-free area.
Human cell lines
The human B cell lines, Raji, Daudi and Namalwa (Burkitt's lymphomas), one T cell line, Molt-4 (acute lymphoblastic leukemia) and the fibrosarcoma HT1080 were obtained from the American Type Culture Collection, Rockville, MD, USA and placed in culture in our laboratory. The Raji, Daudi and Namalwa lines were maintained in RPMI 1640 (Gibco BRL, Grand Island, NY, USA) with 10% fetal bovine serum (FBS) from Hyclone (Logan, UT, USA), 50 U/ml penicillin and 50 g/ml streptomycin (Gibco). Molt-4 was cultured in the same media, with the addition of 1% sodium pyruvate and 1% non-essential amino acids (Gibco). HT1080 was maintained in Earl's MEM (Gibco) with 10% FBS. All cultures were incubated at 37°C in 5% carbon dioxide.
Pretreatment of mice
Treatment groups were made up of five to nine mice each. For precise numbers in each group, see Table 1 . Nude and Rag-1 mice were pretreated with three doses of 200 cGy whole body irradiation from a 137 Cs source 1 week apart prior to cell injection. SCID and NOD/SCID mice were given only 100 cGy per week due to their known increased sensitivity to radiation. 20, 21 Half of the mice receiving radiation were also treated with injections of anti-asialo-GM1 (Wako, Richmond, VA, USA), a rabbit anti-NK cell antibody. The antibody was administered in doses of 25 l per mouse, i.p., immediately prior to cell injection, and again on days 8 and 16 following injection. One-third of the mice in each strain was given no pretreatment.
Cell injection
In order to optimize tumor growth, our tumor cells of interest were mixed with HT1080 fibrosarcoma cells prior to injection. 1 The HT1080 cells were trypsinized, spun and resuspended. They were then given a lethal dose of 6000 cGy radiation from a 137 Cs source and re-suspended in serum-free media at a concentration of 50 × 10 6 cells/ml. Daudi, Raji, Molt-4 and Namalwa were checked for viability by trypan blue dye exclusion, spun, and re-suspended at a concentration of 50 × 10 6 cells/ml. Each cell line was mixed 2:1 with HT1080 and injected subcutaneously into the flanks of mice, for a total dose of 10 × 10 6 cells of interest and 5 × 10 6 HT1080 cells in 0.3 ml media. 
Number shown is means of tumor volumes followed by 95% confidence intervals in parentheses. The second parentheses indicates numbers of animals in each group.
Tumor measurement
Mice were observed to note the beginning of visible tumor growth. From that point on, measurements of two diameters of the tumor (length and width) were made with calipers every 2 days until the mice were moribund. Total tumor volume was estimated using the previously reported formula length × 1/2 width 2 . 22 The mean tumor volume was calculated for each group, and these numbers were arrayed over time. Morbidity in mice given the Namalwa tumor determined the experiment's endpoint.
Statistical analysis
Statistical analysis of results was performed using analysis of variance for repeated measures as implemented in the SAS system's PROCGLIM. 23 
Results
Influence of cell type on tumor growth
Study results are shown graphically in Figure 1 and in tabular form in Table 1 . As expected, the results demonstrated highly significant time effects (Wilk's lambda P = 0.0001). As shown in Figure 1 and Table 1 , cell type significantly influences cell growth (P Ͻ 0.0001). Note that Namalwa tumors grew to the largest size in every treatment group, and that the scale for Namalwa is therefore different from that of the other cell lines. In general, Raji tumors grew larger than Molt-4 tumors, which in turn were larger than Daudi tumors although differences between each of the three latter tumors were not significant.
Figure 1
This figure shows the growth of each of four tumors in NOD/SCID, SCID, Rag-1 and Nude mice; -, NOD/SCID irradiated plus asialoGM1 antibody; ˿-˿, NOD/SCID irradiated; -, NOD/SCID no pretreatment; ¼-¼, SCID irradiated plus asialoGM1 antibody; ᭺-᭺, SCID irradiated; ᭹-᭹, SCID no pretreatment;̆-̆, Nude irradiated plus asialoGM1 antibody; ̅-̅, Nude irradiated;̆-̆, Nude no pretreatment; *-*, Rag-1 irradiated plus asialoGM1 antibody; ×-×, Rag-1 irradiated; +-+, Rag-1 no pretreatment.
Effect of mouse strain on tumor growth
As noted in Figure 1 and Table 1 , we found the differences between the four strains of mice to be highly significant (P Ͻ 0.0001). Tumors grew larger and at the fastest rate in NOD/SCID followed by SCID, Nude and finally Rag-1 mice. In our measurements of mean tumor volume, as seen in Table  1 , tumor size in the three treatment groups of NOD/SCID mice was largest followed by SCID and then other two strains. Statistically, the difference between the mouse strains in determining tumor growth was significant overall (P = 0.0001), and taken separately, the differences between NOD/SCID and each of the other strains individually were significant (P = 0.0001). The differences between the NOD/SCID mice with multiple immune defects compared to other mice with more selective immune deficiencies were very significant in untreated mice.
Effect of irradiation and anti-asialo-GM1 on tumor growth
We examined the effects of additional immunusuppression in the four groups and discovered that the difference between treatments was significant (P = 0.0275). The overall difference is due largely to the inferior performance of the 'no treatment' group as the 'radiation' and 'radiation plus antibody' group were virtually tied (P = 0.9643). This lack of additional antibody effect is very evident in the profoundly immunodeficient NOD/SCID mouse, where addition of radiation or antibody plus irradiation does not enhance tumor growth in a significant way.
Discussion
The present study was developed to compare the ability of genetically compromised mice to support human lymphoma and leukemia cell growth. To our knowledge, this represents the first direct comparison of NOD/SCID, SCID, RAG-1 and nude mice. Because of our interest in the biology and therapy of xenografted human tumors, our focus was to find a model to compare mice with various immunodeficiencies for successful xenotransplantation and maximize durable tumor engraftment and growth of implanted tumors.
Results from these experiments demonstrate, for the first time to our knowledge, that mice with the Rag-1 mutation do support human tumor growth. However, they are less capable of supporting human leukemia and lymphoma xenografts than are NOD/SCID and SCID mice and are even somewhat inferior to Nude mice in support of growth of Raji, Daudi, Namalwa or Molt-4 cells. These results suggest that the immune defects in T and B cells in Rag-1-deficient mice are not as profound as those in SCID mice and even the addition of radiation or antibody treatment does not render Ragdeficient mice profoundly immunodeficient.
As shown in previous studies, human malignancies will grow in NOD/SCID, SCID and Nude mouse models. 14, 16, 19, 24, 25 To our knowledge, there has been no previous comparison of NOD/SCID, SCID and Nude mice in their ability to permit growth of Raji, Daudi or Namalwa lymphoma cells. Previous studies of human leukemias comparing Nude and SCID mice demonstrated the superiority of SCID mice in supporting the growth of BALL-1, Molt-4, CEM and A-1 human leukemia cell lines. 14, 18, 26 The results of these studies were very similar to those of the present investigations which showed the superiority of SCID over Nude mice in the growth of each of the cell lines examined.
A majority of mice from all three strains successfully supported the growth of the tumors examined in this study, but there were some differences which could effect their usefulness in future therapeutic models. First, the strains differed slightly in their rates of tumor uptake. NOD/SCID and SCID mice engrafted 100% of the tumors implanted. Nude mice had a 97% rate of uptake, and Rag-1 mice engrafted 96% of tumors. Some mice had their tumors regress to the point where they could no longer be palpated. In some cases, this was permanent, and in others the tumors re-emerged after a period of days. Regression was seen only rarely in NOD/SCID and SCID mice, but occurred in 17% of Nude mice and 31% of Rag-1 mice.
The literature suggests that immunosuppression of the host prior to implantation can improve transplantability of foreign tissues even in mouse strains with genetic immunodeficiencies. While Nude, SCID and Rag-1 mice lack some or all of their primary cell and antibody-mediated immune response, all three strains maintain robust NK cell activity. 3, 12, 19 Previous studies have demonstrated the efficacy of two methods of residual immune system deactivation: whole body irradiation 2, 15, [27] [28] [29] [30] and injection of asialo-GM1 antibody. 24, 28, 31, 32 Some research has suggested a combined positive effect with both therapies, 30 but this result has been disputed. 18 Our results demonstrate that the use of radiation alone or with antibody to asialo-GM1 enhanced the ability of SCID mice to support selected leukemia and lymphoma cell growth. It is notable that radiation alone, even at the lower levels tolerated by SCID mice, had a positive effect on tumor growth.
Since NOD/SCID mice are known to have significant additional immunologic defects beyond those seen in SCID mice, 13 comparison of this group seemed important. Interestingly, NOD/SCID mice showed the best tumor growth and, in contrast to results seen in SCID, Nude and RAG-1 mice, NOD/SCID mice showed little additional benefit from the addition of radiation or radiation and antibody. The most likely explanation is that NOD/SCID mice are already profoundly immunodeficient in multiple aspects of the immune system and the addition of radiation alone or radiation plus antibody does not significantly enhance the pre-existing immunodeficiency. In conclusion, NOD/SCID mice with previously demonstrated multiple defects of innate and adoptive immunity 13 are the animal of choice for xenotransplanted human leukemias and lymphomas.
